Raymond James Financial’s Niagen Bioscience NAGE Stock Holding History

Raymond James Financial’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07M	Sell	242,411 -69,691	-22%	-$376K	﹤0.01%	3800
2025 Q4	$1.98M	Sell	312,102 -5,823	-2%	-$40.5K	﹤0.01%	3282
2025 Q3	$2.97M	Buy	317,925 +9,711	+3%	+$98.1K	﹤0.01%	2872
2025 Q2	$4.44M	Buy	308,214 +160,136	+108%	+$1.58M	﹤0.01%	2454
2025 Q1	$1.02M	Sell	148,078 -6,151	-4%	-$38.7K	﹤0.01%	3471
2024 Q4	$818K	Buy	+154,229	New	+$844K	﹤0.01%	3582

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial's NAGE Position: Q1 2026 in Review

Raymond James Financial reduced its Niagen Bioscience (NAGE) stake by 22% in Q1 2026, selling an estimated $376K and leaving 242,411 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3800.

Raymond James Financial first reported a position in NAGE in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.44M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

Raymond James Financial held 242,411 shares of Niagen Bioscience worth $1.07M as of Q1 2026.
Raymond James Financial sold 69,691 Niagen Bioscience shares in Q1 2026, an estimated $376K.
Niagen Bioscience made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3800 holding.
Raymond James Financial first reported a position in Niagen Bioscience in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Niagen Bioscience position peaked at $4.44M in Q2 2025.
143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.